Vietnam's Pharmacity raises growth capital from LeapFrog Investments
What's the deal? Pharmacity, Vietnam's largest modern pharmacy chain, has secured growth capital from healthcare-focused investor LeapFrog Investments. Financial terms were not disclosed, though earlier reports suggest the company was targeting around $60M in a mix of equity and debt.
The funds will support the expansion of Pharmacity's network of more than 1,100 stores across Vietnam, including into smaller Tier II and III cities. The chain plans to open 500 new outlets over the next three years.
Founded in 2011, Pharmacity serves nearly 19 million loyalty customers and offers more than 7,000 products spanning medicines, vitamins, supplements, and beauty products. It is also expanding into healthcare services like consultations, diagnostics, and pharmacy benefits management.
Why now? Pharmacity said it achieved profitability for successive quarters since Q4 2025 — a milestone that likely made the timing right to raise growth capital. The company added 140 stores last year and is positioning itself as a broader healthcare platform, not just a retail pharmacy.
LeapFrog, which focuses on financial services, healthcare, and climate solutions, recently exited Goodlife Pharmacy in East Africa — one of the continent's largest pharmacy retail operations. That experience makes Pharmacity a natural next bet.
"With LeapFrog's support, we are ready to accelerate into our next chapter," Pharmacity chief executive officer Deepanshu Madan said.
What could go wrong? Expanding into Tier II and III cities means entering markets with lower purchasing power and less developed infrastructure. Scaling 500 stores in three years is ambitious and will test Pharmacity's operational discipline and capital efficiency.
Vietnam's pharmacy retail market is also getting more competitive, with rivals vying for the same modernisation opportunity. Maintaining profitability while growing aggressively is a delicate balance.
The signal: LeapFrog's move from exiting Goodlife Pharmacy in East Africa to backing Pharmacity in Vietnam suggests a deliberate thesis around scaling modern pharmacy retail in fragmented, underpenetrated markets. With previous backers spanning a Korean corporate (SK GroupDealroom has a profile for this one. Try Dealroom →), a distressed-asset fund (Avenue Capital GroupDealroom has a profile for this one. Try Dealroom →), and secondary specialist TR CapitalDealroom has a profile for this one. Try Dealroom → — which remains the largest shareholder at 22.39% — Pharmacity's cap table reflects a company that has navigated multiple funding cycles; LeapFrog's entry, timed to consecutive profitable quarters, marks a shift toward growth equity backed by a sector-specialist operator.
Read more: dealstreetasia.com
